my account
log out
|
|
my account
log out
|
Anti-BCR immunotoxin (scFv)-PE |
| Create: 02/27/2017 |
| Expired Date: | 02/21/2019 |
| Category: | Drugs&Pharmaceutical [Health&Medical&Pharmaceutical] |
| Message: | This immunotoxin was achieved by conjugating/fusing the Anti-BCR scFv to Pseudomonas exotoxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to cell surface antigens of tumor. Once bind, the toxin enters cells by receptor-mediated endocytosis. Then PE cleaved fragments the size of Mr 37000 and 27000, the large fragment and finally into the Golgi and elongation factor 2 (EM) combining it glycosylation inactivation, inhibition of protein synthesis, leading to apoptosis. It was designed for treating chronic myeloid leukemia (CML). |
 | |
| City: | Shirley[US]
 |
| Location: |
|
| Feb 01 2023 | VBS++ (with Ca and Mg) Buffer | 249 | |
| Feb 01 2023 | GVBE Buffer | 254 | |
| Feb 01 2023 | GVB++ (with Ca and Mg) Buffer | 257 | |
| Feb 01 2023 | Hemolysin (Rabbit Anti-Sheep Cell Hemolysin) | 249 | |
| Aug 30 2019 |  | Anti-HSV-2 gH Antibody | 437 |
| Aug 30 2019 | | Anti-L. major LPG Antibody | 523 |
| Aug 30 2019 | | Anti-DENV-1 Antibody | 429 |
| Aug 30 2019 | | Anti-BPV-1 L1 Antibody | 446 |
| Aug 30 2019 | | Anti-H3N2 HA Antibody | 426 |
| Aug 30 2019 | | Anti-EIAV env Antibody | 457 |
| Copyright © toextrade Inc. All rights reserved. Contact us |